



Fideschem Inc. Commit's to excellence

Company Introduction



- Established in Mar 2012
- Incorporation with two major shareholders

Mr. Nguyen Minh Hieu

Mr. Duong Van Thien

Current working capital: US\$ 650,000



CERTIFICATE OF INCORPORATION (SECTION 7)

The REGISTRAR of CORPORATE AFFAIRS, of the British Virgin Islands HEREBY CERTIFIES, that pursuant to the BVI Business Companies Act, 2004, all the requirements of the Act in respect of incorporation having been complied with,

Fideschem Inc.

BVI COMPANY NUMBER: 1698893

is incorporated in the BRITISH VIRGIN ISLANDS as a BVI BUSINESS COMPANY, this 1st day of March, 2012.



for REGISTRAR OF CORPORATE AFFAIRS
1st day of March, 2012





Total 6 headcounts

Mr. Nguyen Minh Hieu (Pharm.) – Director
 10-year working experience in technical and commercial

Mr. Duong Van Thien (Pharm.) – Vice Director
 9-year working experience in technical and commercial



- Total 6 headcounts (continued...)
 - Mr. Huynh Ngoc Ba (Pharm.) Technical Consultant 25-year working experience in technical site Deputy Chief of R&D and Production in one leading pharmaceutical manufacturer in Vietnam Head of R&D Group in the South of Vietnam.
 - Ph.D Prof. Le Hau (Pharm.) Technical Consultant Deputy Head of Department of Pharmaceutical Industry in University of Pharmaceuticals in Ho Chi Minh City



- Total 6 headcounts (countinued...)
 - Ms. Quach Thu Trang Office Manager
 15-year working experience in logistic and customer service in APIs business
 - Mr. Nguyen Chi Hung Office staff



3PL partner

- CPC No. 1 An government pharmaceutical company with importation, storage and delivery facilities
- Meyer Pharmaceuticals Ltd. (Hong Kong) Associated partner



Business performance

Business revenue:

- 2012 (Apr Dec): Revenue of US\$920,000
- 2013 : Revenue of US\$2,240,000
- 2014: Revenue of US\$3,410,000
- 2015 up-to-date: US\$2,017,996 Increased by 15.5% at the same period



Business performance

Business segments (End of 2014):

APIs business: 92%

Excipient business: 8%



Business performance

Main products:

- Cephalosporin Sterile and Carbapenem Sterile
- Other sterilized APIs
- Statin group
- Imidapril; Perindopril
- Alpha Chymotrypsin
- Oncology APIs
- New diabetics APIs: Gliptin group
- Probiotics
- Mg Stearate, Ca Stearate, Zn Stearate
- Methocel
- Taste masking excipient Indion



Business performance

Main principles:

- Peter Greven (Germany)
- Dow Wolf Cellulose (USA)
- Probioferm (USA)
- Morepen Labs (India)
- Qilu Antibotics (China)
- Yongsun Phama (Korea)
- Savior Lifetec (Taiwan)
- Laurus Lab (India)
- Beijing Geyuantianrun (China)
- Ion Exchanges (India)



Business goal

...till the end of 2017

Revenue: 7 millions US\$

Headcounts: 8 persons

Products: five products as leading products in market



THANK YOU FOR YOUR ATTENTION